Company intelligence / Profile preview

Serono España

Madrid, Madrid, Spain

Ownership: Private
Development stage: Other

Overview

Serono España was the Spanish subsidiary of Serono S.A., a leading global biotechnology company specializing in reproductive health, neurology, and growth and metabolism. The company commercialized prominent biologic therapies in Spain, including Gonal-f for infertility, Rebif for multiple sclerosis, and Saizen for growth hormone deficiency. In June 2007, following the global acquisition of Serono S.A. by Merck KGaA, Serono España was officially absorbed into Merck Farma y Química, S.L., resulting in its dissolution and the integration of its operations into the Merck Group.

Therapeutic areas: EndocrinologyWomen's HealthDermatologyNeurology
Modalities: Recombinant proteinBiologicHormoneMonoclonal antibody
Industry: Biotech

Beyond the preview

Go deeper on Serono España.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Serono España.

Explore the full profile